Immunogenicity and Safety of Three Doses of a Bivalent (B:4:P1.19,15 and B:4:P1.7-2,4) Meningococcal Outer Membrane Vesicle Vaccine in Healthy Adolescents

Author:

Boutriau Dominique12345,Poolman Jan12345,Borrow Ray12345,Findlow Jamie12345,Domingo Javier Diez12345,Puig-Barbera Joan12345,Baldó José María12345,Planelles Victoria12345,Jubert Angels12345,Colomer Julia12345,Gil Angel12345,Levie Karin12345,Kervyn Anne-Diane12345,Weynants Vincent12345,Dominguez Francisco12345,Barberá Ramon12345,Sotolongo Franklin12345

Affiliation:

1. GlaxoSmithKline Biologicals, Rixensart, Belgium

2. Meningococcal Reference Unit, Health Protection Agency, Manchester, United Kingdom

3. Centro de Salud Nazaret, Valencia, Spain

4. Vaccines Institute of Valencia, Valencia, Spain

5. Grupo de Investigación de Atención Primaria de Castellón, Centro de Salud Pública, Castellón, Spain

Abstract

ABSTRACT An experimental bivalent meningococcal outer membrane vesicle (OMV) vaccine (B:4:P1.19,15 and B:4:P1.7-2,4) has been developed to provide wide vaccine coverage particularly of the circulating strains in Europe. A randomized, controlled phase II study (study identification number, 710158/002; ClinicalTrials.gov identifier number, NCT00137917) to evaluate the immunogenicity and safety of three doses of the OMV vaccine when given to healthy 12- to 18-year-olds on a 0-2-4 month ( n = 162) or 0-1-6 month schedule ( n = 159). A control group received two doses of hepatitis A and one of conjugated meningococcal serogroup C vaccine on a 0-1-6 month schedule ( n = 157). Immune response, defined as a fourfold increase in serum bactericidal titer using a range of vaccine-homologous or PorA-related and heterologous strains, was determined for samples taken before and 1 month after vaccination; assays were performed at two laboratories. As measured at the GlaxoSmithKline (GSK) laboratory, the OMV vaccine induced an immune response against homologous or PorA-related strains (in at least 51% of subjects against strains of serosubtype P1.19,15 and at least 66% against strains of serosubtype P1.7-2,4) and against a set of three heterologous strains (in 28% to 46% of subjects). Both laboratories showed consistent results for immune response rates. The OMV vaccine had a similar reactogenicity profile for each schedule. Pain preventing normal activities occurred in approximately one-fifth of the subjects; this was significantly higher than in the control group. The immune responses induced by the bivalent OMV vaccine demonstrated the induction of bactericidal antibodies against the vaccine-homologous/PorA-related strains but also against heterologous strains, indicating the presence of protective antigens in OMVs and confirming the potential of clinical cross-protection.

Publisher

American Society for Microbiology

Subject

Microbiology (medical),Clinical Biochemistry,Immunology,Immunology and Allergy

Reference25 articles.

1. Aase A. T. K. Herstad L. M. Naess T. E. Michaelsen and D. R. Martin. 2004. Opsonophagocytic activity of human sera after vaccination with two different group B meningococcal vaccines in a clinical trial in New Zealand abstr. 63. Abstracts of the 14th International Pathogenic Neisseria Conference Milwaukee Wis.

2. Bjune, G., E. A. Holby, J. K. Gronnesby, O. Arnesen, J. H. Fredriksen, A. Halstensen, E. Holten, A. K. Lindbak, H. Nokleby, and E. Rosenqvist. 1991. Effect of outer membrane vesicle vaccine against group B meningococcal disease in Norway. Lancet338:1093-1096.

3. Borrow, R., I. S. Aaberge, G. F. Santos, T. L. Eudey, P. Oster, A. Glennie, J. Findlow, E. A. Høiby, E. Rosenqvist, P. Balmer, and Martin. 2005. Interlaboratory standardization of the measurement of serum bactericidal activity using human complement against meningococcal serogroup B, strain 44/76-SL, before and after vaccination with the Norwegian MenBvac outer membrane vesicle vaccine. Clin. Diagn. Lab. Immunol.12:970-976.

4. Bos, J. M., H. C. Rümke, R. Welte, M. J. Postma, and J. C. Jager. 2001. Heath economics of an hexavalent meningococcal outer-membrane vesicle vaccine in children: potential impact of introduction in the Dutch vaccination programme. Vaccine20:202-207.

5. Boslego, J., J. Garcia, C. Cruz, W. Zollinger, B. Brandt, S. Ruiz, M. Martinez, J. Arthur, P. Underwood, and W. Silva. 1995. Efficacy, safety and immunogenicity of a meningococcal group B (15:P1.3) outer membrane protein vaccine in Iquique, Chile. Vaccine13:821-829.

Cited by 50 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3